Journal: Gut Microbes

Article Title: Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet

doi: 10.1080/19490976.2023.2178794

Figure Lengend Snippet: Study overview. (a) CONSORT flow diagram for enrollment, allocation, follow-up, and analysis. (b) Metabolic syndrome guidelines as defined by the International Diabetes Foundation (IDF). (c) Heat map depicting the study inclusion criteria met by participants (rows) along with medication use. Those that only satisfied 2 criteria are indicated by an asterisk. Yellow line separates placebo from probiotic arm. HDL = high density lipoprotein; BP = blood pressure (d) Stool and blood samples along with participant food logs were collected over an 18-week period for microbiome and immune system measurements.

Article Snippet: The probiotic supplement contained a proprietary blend of three probiotic strains ( Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM), which were verified through sequencing ( Fig. S1A ), and at least 20 billion colony forming units per capsule.

Techniques:

Journal: Gut Microbes

Article Title: Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet

doi: 10.1080/19490976.2023.2178794

Figure Lengend Snippet: MetSyn parameters did not improve in the probiotic arm, but participants cluster into responder and non-responder groups. (A) MetSyn parameters and (B) alanine aminotransferase (ALT), insulin, and LDL cholesterol at baseline (“B”, week 0) and end of intervention (“W10”, week 10) for probiotic (n=21; participants that had at least 3 elevated parameters and thus met the definition of metabolic syndrome) and placebo arms (n=13). (C) Change from baseline average (weeks -4, -2, 0) to end of intervention (weeks 8, 10) for each participant in placebo, probiotic responder (R), or probiotic non-responder (NR) groups. All probiotic participants (n=26) plotted including those with only 2 elevated parameters (‪ indicates participants that only satisfied 2 criteria for MetSyn). Each row is a participant and is hierarchically clustered by parameters shown. § indicates significant difference between average baseline and end of intervention within the probiotic responders (paired t-test < 0.05). ‡ indicates significant difference between average percent fold change between probiotic responders and placebo (unpaired t-test < 0.05). † indicates significant difference between average baseline and end of intervention within the probiotic non-responders (paired t-test < 0.05). # indicates significant difference between average percent fold change between probiotic non-responders and placebo (unpaired t-test <0.05). (D) Principal coordinate analysis of Euclidean distances for % change in inflammatory marker from baseline (week -3) to end of intervention (week 10) for all participants. Circles denote 50% confidence level for a multivariate t-distribution. (E) Change in serum homovanillic acid levels from baseline (week -3) to end of intervention (week 10) for placebo, probiotic non-responders (NR), and responders (R) (unpaired t-test, post-hoc p-value = 0.004).

Article Snippet: The probiotic supplement contained a proprietary blend of three probiotic strains ( Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM), which were verified through sequencing ( Fig. S1A ), and at least 20 billion colony forming units per capsule.

Techniques: Marker

Journal: Gut Microbes

Article Title: Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet

doi: 10.1080/19490976.2023.2178794

Figure Lengend Snippet: Probiotic responders exhibit distinct microbiome profiles. (a) Within-participant Bray-Curtis distance of amplicon sequenced variants (ASVs) relative to the first baseline time point (week 0) plotted over time by arm (unpaired t-test p values for each time point between arms are shown) (n=13 placebo; n=26 probiotic). (b) Within-participant Bray-Curtis distance, week 0 vs. week 10 by arm and response group (n=14 R; n=12 NR). (c) Bray-Curtis distance of the ASVs for the placebo, probiotic responders and non-responders at the end of the intervention (week 10) are plotted. Circles denote 50% confidence level for a multivariate t-distribution. ASVs driving the separation between groups are depicted as green circles, collapsed to average loading across genus. Size of green circles indicate prevalence (% present across all samples at week 10).

Article Snippet: The probiotic supplement contained a proprietary blend of three probiotic strains ( Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM), which were verified through sequencing ( Fig. S1A ), and at least 20 billion colony forming units per capsule.

Techniques: Amplification

Journal: Gut Microbes

Article Title: Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet

doi: 10.1080/19490976.2023.2178794

Figure Lengend Snippet: Dietary intake differentiating probiotic responders and non-responders. (A) Nutrients that differ between probiotic responders (n=14) and non-responders (n=12) across the entire study (weeks -4 through 14), normalized by median body weight (kg) (siggenes, FDR < 0.05, q-value < 0.1). Scaled nutrient intake is the mean intake value subtracted from each value and divided by the standard deviation. The line within the box plot represents the median value. (B) Scaled average food group intake (weeks 0 and 10) in which the mean value is subtracted from each value and divided by the standard deviation normalized for median body weight between responders and non-responders (sweets; unpaired t-test, p-value = 0.010). The line within the box plot represents the median value.

Article Snippet: The probiotic supplement contained a proprietary blend of three probiotic strains ( Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM), which were verified through sequencing ( Fig. S1A ), and at least 20 billion colony forming units per capsule.

Techniques: Standard Deviation

Journal: Journal of Translational Medicine

Article Title: Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections

doi: 10.1186/s12967-024-05587-9

Figure Lengend Snippet: Properties of Nutraceuticals and Pharmacological interventions to regulate the protective immune activities in alveolar and gut cell linings. A probable modulatory effect of probiotics with supplements to build ILC 3 homeostasis in gut and the functional integrity of the other body organs [ , , – , ]

Article Snippet: NCT04877704 , The effects of symprove, a multi-strain Probiotic, as an Adjuvant in the Management of COVID-19 in Hospitalized Patients , Symprove probiotics , Length of Hospital Stay, intestinal inflammation, symptoms recovery in 3 months.

Techniques: Probiotics, Functional Assay

Journal: Journal of Translational Medicine

Article Title: Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections

doi: 10.1186/s12967-024-05587-9

Figure Lengend Snippet: The interventional studies are being carried out using probiotics in COVID-19 individuals with expected outcome (ClinicalTrials.gov—U.S. National Library of Medicine)

Article Snippet: NCT04877704 , The effects of symprove, a multi-strain Probiotic, as an Adjuvant in the Management of COVID-19 in Hospitalized Patients , Symprove probiotics , Length of Hospital Stay, intestinal inflammation, symptoms recovery in 3 months.

Techniques: Probiotics, Infection, Maltodextrin, Starch, Capsules, Bacteria, Activation Assay, Biomarker Assay, Adjuvant

Journal: BioMed Research International

Article Title: Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An In Vitro Investigation

doi: 10.1155/2014/380316

Figure Lengend Snippet: Probiotic bacteria selected for investigations into cholesterol assimilation based on previous cholesterol-lowering work.

Article Snippet: One probiotic strain, L. reuteri NCIMB 701089 ( P < 0.05, subset “a”), demonstrated the most assimilation, when cholesterol assimilation is normalized for viability counts, with 2254.70 ± 63.33 mg of cholesterol assimilated per 10 10 cells.

Techniques: Bacteria

Journal: BioMed Research International

Article Title: Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An In Vitro Investigation

doi: 10.1155/2014/380316

Figure Lengend Snippet: (a) Viability and (b) cholesterol assimilation of probiotic Lactobacillus in MRS containing 100 μ g/mL of cholesterol, following 24 h of incubation. Data is represented as means ± SEM, n = 3. Tukey's homogeneous subsets generated from pairwise comparisons are represented as a, b, c, d, and e, with “a” representing the most significant subset from control.

Article Snippet: One probiotic strain, L. reuteri NCIMB 701089 ( P < 0.05, subset “a”), demonstrated the most assimilation, when cholesterol assimilation is normalized for viability counts, with 2254.70 ± 63.33 mg of cholesterol assimilated per 10 10 cells.

Techniques: Incubation, Generated, Control

Journal: BioMed Research International

Article Title: Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An In Vitro Investigation

doi: 10.1155/2014/380316

Figure Lengend Snippet: Percent cholesterol assimilation by Lactobacillus strains in MRS containing 100 μ g/mL of cholesterol-PEG 600 for 24 h and the amount of cholesterol assimilation expected in a probiotic dose containing 10 10 cells.

Article Snippet: One probiotic strain, L. reuteri NCIMB 701089 ( P < 0.05, subset “a”), demonstrated the most assimilation, when cholesterol assimilation is normalized for viability counts, with 2254.70 ± 63.33 mg of cholesterol assimilated per 10 10 cells.

Techniques: Control

Journal: BioMed Research International

Article Title: Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An In Vitro Investigation

doi: 10.1155/2014/380316

Figure Lengend Snippet: (a) Viability and (b) cholesterol assimilation of probiotic Lactobacillus in simulated intestinal fluid containing 100 μ g/mL of cholesterol, following 24 h of incubation. Data is represented as means ± SEM, n = 3. Tukey's homogeneous subsets generated from pairwise comparisons are represented as a, b, c, d, e, and f, with “a” representing the most significant subset from control.

Article Snippet: One probiotic strain, L. reuteri NCIMB 701089 ( P < 0.05, subset “a”), demonstrated the most assimilation, when cholesterol assimilation is normalized for viability counts, with 2254.70 ± 63.33 mg of cholesterol assimilated per 10 10 cells.

Techniques: Incubation, Generated, Control

Journal: BioMed Research International

Article Title: Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An In Vitro Investigation

doi: 10.1155/2014/380316

Figure Lengend Snippet: Percent cholesterol assimilation by Lactobacillus strains in simulated intestinal fluid containing 100 μ g/mL of cholesterol-PEG 600 for 24 h and the amount of cholesterol assimilation expected in a probiotic dose containing 10 10 cells.

Article Snippet: One probiotic strain, L. reuteri NCIMB 701089 ( P < 0.05, subset “a”), demonstrated the most assimilation, when cholesterol assimilation is normalized for viability counts, with 2254.70 ± 63.33 mg of cholesterol assimilated per 10 10 cells.

Techniques: Control

Journal: BioMed Research International

Article Title: Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An In Vitro Investigation

doi: 10.1155/2014/380316

Figure Lengend Snippet: Schematic representation of probiotic cholesterol assimilation mechanism. (a) Cholesterol absorption by the intestinal enterocytes increases cardiovascular disease risks. (b) Probiotic administration enhances cholesterol assimilation, leading to the excretion of nonmetabolized cholesterol and other lipid molecules decreasing cardiovascular disease risks.

Article Snippet: One probiotic strain, L. reuteri NCIMB 701089 ( P < 0.05, subset “a”), demonstrated the most assimilation, when cholesterol assimilation is normalized for viability counts, with 2254.70 ± 63.33 mg of cholesterol assimilated per 10 10 cells.

Techniques:

Journal: International Journal of Medical Sciences

Article Title: Multi-Strain Probiotics Inhibit Cardiac Myopathies and Autophagy to Prevent Heart Injury in High-Fat Diet-Fed Rats

doi: 10.7150/ijms.14769

Figure Lengend Snippet: Masson's trichrome staining of cardiac tissue sections. Histopathological analysis of cardiac tissue sections of the left ventricle from the control rats, the high-fat diet-induced obese rats, the high-fat diet-fed rats treated with low dose, medium dose and high dose of multi-strain probiotics. White arrow: site of collagen accumulation.

Article Snippet: Multi-strain probiotic powder ( Lactobacillus rhamnosus: Pediococcus acidilactici : Bifidobacterium adolescentis ; 1: 1: 1) was produced by freeze-drying and obtained from New Bellus Enterprise Co., Ltd (Tainan, Taiwan).

Techniques: Staining, Control, Probiotics

Journal: International Journal of Medical Sciences

Article Title: Multi-Strain Probiotics Inhibit Cardiac Myopathies and Autophagy to Prevent Heart Injury in High-Fat Diet-Fed Rats

doi: 10.7150/ijms.14769

Figure Lengend Snippet: Fibrosis-related protein expression analysis via Western blot. The fibrosis-related protein levels were increased in the left ventricular tissue of high-calorie diet-induced obese rats, whereas treatment with different doses of multi-strain probiotics reduced these fibrosis-related proteins. (A) Western blots for the fibrosis pathway proteins. Quantitative analysis of the expression levels of (B) MMP2 or (C) TGF-β normalized to those of tubulin, #P<0.05, ##P<0.01 or ###P<0.001: the mean values were significantly different from those of the control group.

Article Snippet: Multi-strain probiotic powder ( Lactobacillus rhamnosus: Pediococcus acidilactici : Bifidobacterium adolescentis ; 1: 1: 1) was produced by freeze-drying and obtained from New Bellus Enterprise Co., Ltd (Tainan, Taiwan).

Techniques: Expressing, Western Blot, Probiotics, Control

Journal: International Journal of Medical Sciences

Article Title: Multi-Strain Probiotics Inhibit Cardiac Myopathies and Autophagy to Prevent Heart Injury in High-Fat Diet-Fed Rats

doi: 10.7150/ijms.14769

Figure Lengend Snippet: Autophagy early stage-related protein expression analysis via Western blot. The autophagy-related protein levels were increased in the left ventricular tissue of high-calorie diet-induced obese rats, whereas treatment with different doses of multi-strain probiotics reduced these fibrosis-related proteins. (A) Western blots for the fibrosis pathway proteins. Quantitative analysis of the expression levels of (B) LC3B or (C) ATG7 normalized to those of tubulin, #P<0.05, ##P<0.01 or ###P<0.001: the mean values were significantly different from those of the control group.

Article Snippet: Multi-strain probiotic powder ( Lactobacillus rhamnosus: Pediococcus acidilactici : Bifidobacterium adolescentis ; 1: 1: 1) was produced by freeze-drying and obtained from New Bellus Enterprise Co., Ltd (Tainan, Taiwan).

Techniques: Expressing, Western Blot, Probiotics, Control

Journal: International Journal of Medical Sciences

Article Title: Multi-Strain Probiotics Inhibit Cardiac Myopathies and Autophagy to Prevent Heart Injury in High-Fat Diet-Fed Rats

doi: 10.7150/ijms.14769

Figure Lengend Snippet: ICH staining of cardiac tissue sections. Histopathological analysis of cardiac tissue sections of the left ventricle from the control rats, the high-fat diet-induced obese rats, the high-fat diet-fed rats treated with low dose, medium dose and high dose of multi-strain probiotics. Brown color: site of LC3B expression.

Article Snippet: Multi-strain probiotic powder ( Lactobacillus rhamnosus: Pediococcus acidilactici : Bifidobacterium adolescentis ; 1: 1: 1) was produced by freeze-drying and obtained from New Bellus Enterprise Co., Ltd (Tainan, Taiwan).

Techniques: Staining, Control, Probiotics, Expressing

Journal: International Journal of Medical Sciences

Article Title: Multi-Strain Probiotics Inhibit Cardiac Myopathies and Autophagy to Prevent Heart Injury in High-Fat Diet-Fed Rats

doi: 10.7150/ijms.14769

Figure Lengend Snippet: Hypertrophy-related protein expression analysis via Western blot. The autophagy-related protein levels were increased in the left ventricular tissue of high-calorie diet-induced obese rats, whereas treatment with different doses of multi-strain probiotics reduced these fibrosis-related proteins. (A) Western blots for the fibrosis pathway proteins. Quantitative analysis of the expression levels of (B) ERK5, (C) MEK5, (D) uPA and (E) ANP normalized to those of tubulin, #P<0.05, ##P<0.01 or ###P<0.001: the mean values were significantly different from those of the control group.

Article Snippet: Multi-strain probiotic powder ( Lactobacillus rhamnosus: Pediococcus acidilactici : Bifidobacterium adolescentis ; 1: 1: 1) was produced by freeze-drying and obtained from New Bellus Enterprise Co., Ltd (Tainan, Taiwan).

Techniques: Expressing, Western Blot, Probiotics, Control